According to Zacks, “Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company’s lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montréal, Canada. “
Several other equities research analysts have also recently issued reports on the stock. ValuEngine upgraded shares of Milestone Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, October 1st. Cowen reiterated a buy rating and set a $32.00 price objective on shares of Milestone Pharmaceuticals in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $30.10.
Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). Sell-side analysts expect that Milestone Pharmaceuticals will post -3.29 earnings per share for the current fiscal year.
In other Milestone Pharmaceuticals news, major shareholder Rtw Investments, Lp purchased 5,487 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average price of $18.95 per share, for a total transaction of $103,978.65. Also, major shareholder Stonepine Capital, L.P. purchased 100,000 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Friday, October 11th. The stock was acquired at an average price of $0.63 per share, for a total transaction of $63,000.00. Insiders purchased 113,637 shares of company stock worth $311,967 in the last 90 days.
A number of institutional investors and hedge funds have recently made changes to their positions in MIST. Tower Research Capital LLC TRC bought a new stake in Milestone Pharmaceuticals in the second quarter worth $51,000. Landscape Capital Management L.L.C. bought a new stake in Milestone Pharmaceuticals in the second quarter worth $459,000. Pentwater Capital Management LP bought a new stake in Milestone Pharmaceuticals in the second quarter worth $679,000. VHCP Management II LLC bought a new stake in Milestone Pharmaceuticals in the second quarter worth $4,033,000. Finally, Zimmer Partners LP bought a new stake in Milestone Pharmaceuticals in the second quarter worth $4,344,000. Institutional investors own 53.33% of the company’s stock.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.